Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals by Byakika-Kibwika, Pauline et al.
SAGE-HindawiAccess to Research
Malaria Research and Treatment
Volume 2011, Article ID 703730, 5 pages
doi:10.4061/2011/703730
Review Article
Artemether-Lumefantrine CombinationTherapy for
TreatmentofUncomplicated Malaria: ThePotentialfor
Complex Interactionswith Antiretroviral Drugsin
HIV-InfectedIndividuals
PaulineByakika-Kibwika,1,2 Mohammed Lamorde,1,2 HarrietMayanja-Kizza,1
SayeKhoo,3 ConceptaMerry,1,2 and Jean-PierreVangeertruyden4
1Infectious Diseases Institute and Infectious Diseases Network for Treatment and Research in Africa (INTERACT),
Makerere University College of Health Sciences, P.O. Box 7061, Kampala, Uganda
2Department of Pharmacology and Therapeutics, Trinity College Dublin 2, Ireland
3Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3BX, UK
4International Health, Epidemiology en Social Medicine, Universiteit Antwerpen, Universiteitsplein 1, 2610 Antwerp, Belgium
Correspondence should be addressed to Pauline Byakika-Kibwika, pbyakika@gmail.com
Received 14 December 2010; Accepted 14 February 2011
Academic Editor: Neena Valecha
Copyright © 2011 Pauline Byakika-Kibwika et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Treatment of malaria in HIV-infected individuals receiving antiretroviral therapy (ART) poses signiﬁcant challenges. Artemether-
lumefantrine (AL) is one of the artemisisnin-based combination therapies recommended for treatment of malaria. The drug
combination is highly eﬃcacious against sensitive and multidrug resistant falciparum malaria. Both artemether and lumefantrine
aremetabolizedbyhepaticcytochromeP450(CYP450)enzymeswhichmetabolizetheproteaseinhibitors(PIs)andnonnucleoside
reversetranscriptaseinhibitors(NNRTIs) used forHIV treatment. CoadministrationofNNRTIs andPIswithALcouldpotentially
cause complex pharmacokinetic drug interactions. NNRTI by inducing CYP450 3A4 enzyme and PIs by inhibiting CYP450 3A4
enzymes could inﬂuence both artemether and lumefantrine concentrations and their active metabolites dihydroartemisinin and
desbutyl-lumefantrine, predisposing patients to poor treatment response, toxicity, and risk for development of resistance. There
are scanty data on these interactions and their consequences. Pharmacokinetic studies to evaluate these interactions in the target
populations are urgently needed.
1.Introduction
Human immunodeﬁciency virus (HIV) and malaria have
overlapping geographical distribution. Together, the two
diseases account for 4 million deaths a year worldwide [1].
Over90%oftheworldmalariaburdenoccursinsub-Saharan
Africa, the region with 67% of the global HIV burden. Given
the extensive overlap in geographical distribution of the
two diseases, any interaction between the two could have
profound public health consequences. In areas with stable
malaria transmission, HIV increases risk of malaria infection
and clinical malaria especially in individuals with advanced
immunosuppression and in areas with unstable malaria
transmission; HIV-infected individuals are at increased risk
for severe malaria and death [1, 2].
This vulnerable population requires prompt, safe and
eﬀective antimalarial treatment. Current guidelines for
malaria treatment advocate use of artemisinin-based com-
bination therapies (ACTs). Treatment of malaria in HIV-
infected individuals receiving ART poses signiﬁcant chal-
lenges with gaps in the knowledge of ART and ACT drug-
drug interactions and their consequences.
Antiretroviral drugs are among the most therapeutically
risky drugs for drug-drug interactions due to the potent
inhibition and induction of cytochrome (CYP) enzymes
as well as transport proteins. The combination of at least2 Malaria Research and Treatment
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drug-drug interactions. The risk of clinically signiﬁcant
interactions involving ART when coadministered with sub-
s t r a t e so fC Y Pe n z y m e si sc o n s i d e r a b l ea n dm a yr e s u l t
in high concentrations with excessive toxicity or reduced
concentrations with reduced eﬃcacy and risk for devel-
opment of resistance. Clinically signiﬁcant CYP-mediated
drug-drug interactions are more likely to occur with non
nucleoside reverse transcriptase inhibitors (NNRTs) and
proteaseinhibitors-(PIs-)basedARTregimensbecausethese
are substrates, inducers, and/or inhibitors of CYP enzymes
which metabolize the majority of drugs and xenobiotics [3].
Nucleoside reverse transcriptase inhibitors do not undergo
CYP-mediated metabolism and are less likely to cause CYP-
mediated drug interactions. They may cause interactions
by inﬂuencing absorption, distribution, and elimination of
coadministered drugs.
2.Artemether-LumefantrineUse in
Treatmentof Malaria
Artemether and lumefantrine have diﬀerent modes of action
and act at diﬀerent points in the parasite life cycle. Oral
formulations of AL are available as tablet and dispersible
formulations with similar pharmacokinetic properties [4, 5].
A six-dose regimen of artemether (20mg) coformulated
with lumefantrine (120mg) is recommended; with ﬁrst and
second doses taken eight hours apart, the third dose is taken
24 hours after the ﬁrst and the remaining doses 12 hours
apart [6, 7]. Food enhances absorption of both artemether
and lumefantrine although this eﬀect is more apparent for
lumefantrine [8–10]. The typical fat content of African
diets has been demonstrated to be adequate for optimal
absorption of AL [11], although the loss of appetite, nausea
and vomiting in patients with malaria may compromise fat
intake. Plasma concentrations of lumefantrine remain high
with repeated doses over the 3 day course; however, poor
adherence to the 3-day regimen may reduce eﬀectiveness
of AL. In multidrug resistant areas, day 7 lumefantrine
concentration was a useful surrogate marker for AUC and
concentrations of less than 280ng/mL predicted treatment
failure [9, 12].
Eﬃcacy of the 6-dose regimen of AL is consistently
greaterthan95%,withrapidparasiteandsymptomclearance
and signiﬁcant gametocidal eﬀect [4, 13–17]. A few cases of
treatment failure are recorded after AL treatment; however,
these are mostly reinfections [18–21]. This is of particular
concern in areas with very intense malaria transmission
where antimalarial drugs with longer half-life may oﬀer the
advantage of preventing reinfection. It is also of concern
in HIV-infected individuals who are at increased risk for
malaria infection [22]. Useofcotrimoxazole prophylaxisand
insecticidetreated bednetsmarkedly reducestheincidenceof
malaria in HIV-infected individuals and are recommended.
AL is safe and well tolerated. Majority of adverse
events are of mild or moderate severity mostly aﬀecting
gastrointestinal and nervous systems; however, most are
typical of the symptomatology of malaria or concomitant
infections [4, 14–17, 23]. Although lumefantrine possesses
similar chemical structure with halofantrine which is known
to cause cardiac arrhythmia and sudden death, safety studies
have not shown lumefantrine to be cardiotoxic or to prolong
QTc interval at therapeutic doses [24, 25].
3.PharmacologyofArtemether
Artemether is derived from the Chinese herb sweet worm-
wood (Artemisua annua). The antimalarial properties of
artemether stem from interference with parasite transport
proteins, disruption of parasite mitochondrial function,
inhibition of angiogenesis, and modulation of host immune
function [26]. Artemether is absorbed very rapidly after oral
administration reaching peak plasma concentrations within
2 hours after dose [8, 10, 12]. It has a half-life of 1–3
hours. It is metabolized quickly via CYP450 2B6, CYP450
3A4 and possibly CYP450 2A6 [27, 28]t ot h em o r ep o t e n t
antimalarial metabolite DHA, which in turn is converted
to inactive metabolites primarily by glucuronidation via
UGT1A1, 1A8/9 and 2B7 [27]. Artemether induces CYP450
2C19 and 3A4 [28]. DHA reaches maximum plasma con-
centration within 2-3 hours after dosing. Artemether acts
rapidly to clear malaria parasites from circulation. Both
artemether and DHA oﬀer potent antimalarial properties
causing signiﬁcant reduction in asexual parasite mass of
approximately 10,000 fold (4 log) per reproductive cycle,
with prompt resolution of symptoms [29, 30].
4.PharmacologyofLumefantrine
Lumefantrine is an aryl-amino alcohol [27]t h a tp r e v e n t s
detoxiﬁcationofheam,suchthattoxicheamandfreeradicals
induce parasite death [31]. Lumefantrine absorption occurs
2 hours after oral intake reaching peak plasma concentration
a f t e r3 - 4h o u r s[ 9]. It has a half life of 3–6 days and
is responsible for preventing recurrent malaria parasitemia
[32]. It is absorbed and cleared slowly acting to eliminate
residual parasites that may remain after artemether and
DHA have been cleared from the body and thus prevents
recrudescence [8, 31]. Lumefantrine is metabolized by N-
debutylation mainly by CYP450 3A4 [27, 28]t od e s b u t y l -
lumefantrine with 5–8-fold higher antiparasitic eﬀect than
lumefantrine. Lumefantrine inhibits CYP450 2D6 [28].
5.PharmacologyofAntiretroviralDrugs
Current guidelines for treatment of HIV in most resource
limitedsettings recommendcombinationtherapyof2NRTIs
and 1 NNRTI as initial treatment for ART na¨ ıve patients
and for patients with treatment failure; 2NRTIs and 1 PI are
recommended. The NRTIs are analogues of naturally occur-
ring deoxynucleotides needed to synthesize viral DNA. They
are well absorbed after oral administration; however, NRTIs
must be converted to their active metabolites, NRTI triphos-
phates, intracellularly, after endocytosis by addition of three
phosphate groups to their deoxyribose moiety, a reaction
catalyzed by cellular kinase enzymes. The triphosphateMalaria Research and Treatment 3
metabolites compete with the natural deoxynucleotides for
incorporation into the viral DNA chain. Their incorporation
inhibits formation of phosphodiester bridges and prevents
viralDNAsynthesisandelongation.MostNRTIsareexcreted
unchanged through the kidney while zidovudine is excreted
via the liver through glucoronidation.
The NNRTIs inhibit reverse transcriptase enzyme by
binding directly and noncompetitively to the enzyme at a
position in close proximity to the substrate binding site for
nucleosides inducing conformational changes that impact
enzyme catalytic activities. The resulting complex blocks the
catalyst activated binding site which in turn, binds fewer
nucleosides, slowing down polymerization signiﬁcantly [33].
Nevirapine and Efavirenz are the two NNRTIs available for
use in most malaria endemic regions [34].
6.Nevirapine
Nevirapine is administered with a dose escalation schedule
starting at an adult dose of 200mg once daily for 2 weeks
followed by 200mg twice daily thereafter because of the
potential for adverse events and metabolic autoinduction
of CYP450 enzymes. Absorption is not aﬀected by food,
acids, or alkali, and more than 90% of the administered
dose is absorbed after oral intake [35] with bioavailability
of more than 90% and about 60% protein binding.[36]
The elimination half life is 25–30 hours. It is distributed
throughout the body [35], metabolized by CYP450 3A4 and
2 B 6 ,a n de x c r e t e dv i at h el i v e ra n dk i d n e y si nt h ef o r mo f
glucuronide conjugates of hydroxylated metabolites [35]. It
isbothasubstrateandinducerofCYP4503A4,and2B6[36].
Tolerability to nevirapine in majority of patients is
relatively good [37]. The adverse event most commonly
observed is a hypersensitivity rash, occurring in about 16%
of patients with about 7% experiencing grade 3 or 4 rash
with the Steven Johnson syndrome. Hypersensitivity is more
common during the ﬁrst 6 weeks of treatment [35]. The
secondcommonadverseeventishepatotoxicitywithelevated
liver enzymes. Female sex and a high CD4 cell count
are associated with higher incidence of nevirapine-induced
hypersensitivity [35, 38].
7.Efavirenz
Efavirenz is available as capsules, ﬁlm-coated tablets and liq-
uid formulation for oral administration. The recommended
adult dose is 600mg od, taken on an empty stomach,
preferably at bedtime to diminish possible neuropsychiatric
side eﬀects that are enhanced with increased bioavailability
in presence of food. It is highly protein bound (>99%),
predominantly to albumin [39]. Oral bioavailability is good;
reaching peak plasma concentrations within 3–5 hours after
dose administration. It has a long serum half-life of 45 hours
and reaches steady-state plasma concentrations in 6 to 10
days [40]. Efavirenz is a substrate, inhibitor and inducer of
several CYP450 enzymes (2B6, 3A4, 2A6, 2C9, and 2C19)
and induces its own metabolism [39]. It is metabolized
to inactive hydroxylated metabolites that include 8-hydoxy
and 7-hydroxyefavirenz. Hydroxylated efavirenz metabolites
undergo subsequent urinary and biliary excretion after
conjugation mainly glucuronidation.
The safety proﬁle of efavirenz is good with minor side
eﬀects including skin rash and neuropsychiatric events. The
rash is maculopapular, often of mild to moderate intensity
(grade 1 or 2), occurring between the ﬁrst and third week
of treatment with incidence up to 34% [40]. It resolves
spontaneously within one month or with treatment inter-
ruption, after which efavirenz may be reinitiated cautiously.
The incidence of grade 3 or 4 rash with Stevens-Johnson
syndrome is only 0.1%, and once it occurs, treatment
shouldbestoppedimmediately.Neuropsychiatriceventsmay
occur including dizziness, insomnia, somnolence, impaired
concentration, vivid dreams, and nightmares. More severe
events like severe depression, suicidal ideation, nonfatal
suicidal attempts, aggressive behaviour, paranoid, and manic
reactions seldom occur [41]. Hepatotoxicity has been shown
to occur during efavirenz treatment [38]w i t hi n c r e a s e dr i s k
in patients with chronic viral hepatitis. Other side eﬀects
include gynaecomastia, increase in HDL-cholesterol, and
elevated triglycerides.
8.Lopinavir/Ritonavir
The PIs prevent viral replication by inhibiting activity of
the HIV protease enzyme and preventing HIV from being
successfully assembled and released from the infected CD4
cell. HIV-1 protease is an aspartic protease that cleaves
both structural and functional proteins from precursor viral
polypeptide strands. Inhibition of the protease produces
immature, noninfectious virions, thus preventing subse-
quent cellular infection [42]. Lopinavir coformulated with
ritonaviristhemostfrequentlyprescribedPIinmostmalaria
endemic regions.
Lopinavir is 3 to 4 times more active against HIV than
ritonavir; however, when lopinavir is administered alone,
it exhibits poor bioavailability. Lopinavir is metabolized
extensibly by CYP450 3A4 and coadministration with riton-
avir which is a potent inhibitor of CYP450 3A4 results in
increased and sustained concentrations of lopinavir [43].
Both drugs are primarily eliminated by the fecal route with
urinary excretion accounting for <2% ofthe eliminated drug
[44]. The co-formulation is available in tablet formulation
called (Aluvia) for adults, each tablet containing 200mg
lopinavir and 50mg ritonavir.
The standard dose is 400mg/100mg twice daily in
treatment experienced patients. Combination therapy with
lopinavir/ritonavir containing regimens is well tolerated and
eﬀectiveinsuppressingHIV-RNAandincreasingCD4+ Tcell
counts [43] .T h em o s tf r e q u e n ts i d ee ﬀectsare generally mild
to moderate and mainly in the gastrointestinal system where
diarrhea, nausea, and vomiting may occur. Other side eﬀects
are hypertriglyceridemia, hypercholesterolemia, pancreatitis,
transient elevationsintransaminase levels,insulin resistance,
new onset diabetes, and worsening of pre-existing diabetes.
Fat redistribution occurs with central obesity, dorsocervical
fat enlargement (buﬀalo hump), peripheral wasting, facial4 Malaria Research and Treatment
wasting, breast enlargement, and cushingoid appearance.
Less common adverse eﬀects include allergic reaction, asthe-
nia, malaise, headache, myalgias, arthralgias, myocardial
infarction, seizures, and lactic acidosis [43].
9.PotentialforPharmacokinetic
InteractionsbetweenALand ART
9.1. Eﬀect of ART on AL. Coadministration of NNRTI or PI-
based ARTwith AL could potentially cause drug interactions
with eﬀects on the plasma concentrations of artemether and
lumefantrine with unknown eﬀects on parasite clearance
and adverse eﬀects. There are very scanty data on these
interactions and their eﬀects, yet AL and ART continue to
be coprescribed in malaria endemic regions. A study that
investigated the pharmacokinetics of the standard 6 dose
of AL as 80/480mg twice daily when administered with
lopinavir/ritonavir 400/100mg twice daily in healthy HIV-
seronegative volunteers demonstrated 2- to 3-fold increases
in lumefantrine AUC and trends towards decreases in
artemether Cmax and AUC with decrease in DHA AUC.
The authors concluded that coadministration of AL and
lopinavir/ritonavir can be carried out but highlighted the
need for formal safety analysis of concomitant therapy
[45]. Data from another pharmacokinetics study of HIV-
infected participants without malaria, surprisingly demon-
strated signiﬁcantly increased lumefantrine exposure when
coadministered with nevirapine although toxicity was not
increased [46].
9.2. Eﬀect of AL on ART. It is not known what plasma levels
of ART will result if AL is administered with ART; however,
since malaria infection occurs as an acute illness requiring a
short course of therapy, the eﬀect of AL on ART may only
be transient with clinically insigniﬁcant results. However, in
malaria endemic regions, where individuals are exposed to
repeated malaria infections requiring treatment, the eﬀect
of drug interactions combined with the transient increase in
viral replication and viral load [47]m a yb es i m i l a rt oe ﬀects
of suboptimal adherence to ART.
10.Conclusion
There is potential for pharmacokinetic drug interactions
between AL and NNRTIs and PIs in HIV-infected patients
with malaria. Data on these interactions is sparse. These
interactions, if not properlyaddressed, might have animpact
on the Useful Therapeutic Lives (UTL) of the concerned
drugs. Results of pharmacokinetic studies evaluating these
interactions in depth and their implications are needed.
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